Nexia CEO Dr. Jeffrey Turner Joins the Board of Dope.de

GUELPH, ON, Sept. 23 /CNW/ - Dope.de, a subsidiary of GUARD INC. (ASE:GUA), announced today that Dr. Jeffrey D. Turner, President and CEO of Nexia Biotechnologies Inc., has been appointed to the Board of Directors of Dope.de Dr. Turner is also a director of GUARD INC.

``Having Dr. Turner join the Board of Dope.de at this important stage in our development is a vote of confidence in our EMD technology and its commercial potential,'' commented Mr. Percy Skuy, Chairman of the Board of Directors of Dope.de. ``As the President and CEO of a successful biotechnology company, Dr. Turner will provide the management team of Dope.de with valuable experience and insight with respect to the financing and commercialization of our novel drug design technology.''

Dr. Jeffrey D. Turner is President and CEO of Nexia Biotechnologies Inc., Canada's largest producer of recombinant biomaterials (Biosteel(R)) and therapeutics via animal transgenics. In addition to serving on the Boards of GUARD and Dope.de, Dr. Turner is a member of the Boards of Montreal-based investment fund T2C2 and Biovet Inc. a veterinarian healthcare company, located in St. Hyacinthe, Quebec. Dr. Turner, who is an Adjunct Professor in the Department of Animal Science at McGill University, shares credit for a number of patents and numerous scientific publications and serves on several  committees related to animal biotechnology.

Dope.de is an innovative therapeutic molecular design company based upon Evolutionary Molecular Design™ (EMD), a proprietary technology. The EMD process, which is protected by patents, is a powerful drug design tool with the ability to design new chemical entities with specified biological activity and predicted physical and chemical properties. This new platform technology is currently being applied to several areas of oncology and is believed by the company to be the most advanced and integrated weed discovery technology in use today.